Raley’s and Organic Bistro help diabetics
SACRAMENTO, Calif. Supermarkets under Raley’s banners are teaming up with Organic Bistro Whole Life Meals to provide free classes, educational material and low-priced healthy products for consumers with diabetes.
As part of the program, Raley’s corporate dietitian Earline Griffith is visiting many of Raley’s 129 stores on a tour to conduct classes educating diabetics on how to better manage their condition and lead a healthier life.
“We want to provide customers fighting diabetes with resources and realistic meal solutions so that achieving a healthy lifestyle is convenient,” said Griffith.
In support of Raley’s educational outreach, Organic Bistro is providing customers with coupons for its frozen entree products that are available at Raley’s stores including Raley’s Supermarkets, Bel Air Markets and Nob Hill Foods. The coupons are for its line of Whole Life Meals, which are suitable for diabetics because they contain a low glycemic index and load, which measures how quickly foods turn into sugar.
Publix postpones Miracle Mile GreenWise opening
VERO BEACH, Fla. Publix Super Markets has placed on hold plans to open a Publix GreenWise organic grocer here, according to reports published Wednesday.
Plans for the Vero Beach store have slowed while the grocer focuses on opening its GreenWise concept in Boca Raton, Kim Jaeger, Publix spokeswoman, told Stuart News Group.
According to the Stuart News report, Publix had announced last September the first GreenWise Market would open on Miracle Mile in Vero Beach during the third quarter of 2008.
FDA approves new cancer drug from Cephalon
WASHINGTON The Food and Drug Administration ahs announced its approval of Cephalon’s new cancer drug, Treanda. This recent approval hopes to raise the company’s shares, which have fallen 29 percent since June, published reports claim.
Treanda, indicated for chronic lymphocytic leukemia, was granted priority review by the FDA. The FDA approval of Treanda will mark the first big step in the oncology department for Cephalon, which normally makes its sales on pain relievers and treatments for central-nervous-system disorders. According to reports, the approval of this drug will bring it close to competing with major drug companies.
The approval of Treanda not only is expected to raise the share price of the company, but will also pave the way for Cephalon to introduce more cancer-related drugs into the market. As a result, shares of Cephalon were up $2.79, or 4.7 percent, to $62.14.